EDAP TMS goes into its Q1 2026 earnings call on May 7 carrying a month of losses and a freshly cut analyst target — with options traders, unusually, leaning the other way.
The most pressing backdrop is the price. EDAP closed at $3.31 on April 29, down 11% over the past month and off 2% on the week. That leaves the stock trading at a steep discount to the Street's mean target of $5.50 — a gap implying roughly 66% upside on paper. The discount is genuine: HC Wainwright trimmed its target from $14 to $10 on April 9, maintaining a Buy, acknowledging that the path to recovery is taking longer than hoped. Piper Sandler holds an Overweight with a $4.50 target. The Jefferies downgrade to Hold in April 2025 — now a year old — rounds out a thin but predominantly bullish coverage picture. Despite the target cuts, no analyst covering the name has moved to Sell, which keeps the directional bias positive even as conviction narrows.
Options positioning adds a mild counterpoint to the bearish price action. The put/call ratio has eased to 0.48, a touch below its 20-day average of 0.53, suggesting options participants have grown slightly less hedged relative to recent weeks. That diverges from the typical pre-earnings pattern of rising put demand. The PCR's 52-week range runs from 0.09 to 0.63, so current readings are firmly in the middle; this is not a conviction signal in either direction, but the mild call skew is notable given how far the stock has fallen.
The short side tells an almost entirely benign story. Short interest amounts to just 0.13% of the free float — a trivially small position relative to the total share count. Borrowing costs are subdued at around 1%, and borrow availability sits at over 2,270% of current short interest, meaning there is an enormous pool of supply relative to demand. Whatever pressure EDAP faces heading into earnings, it is not coming from bears building meaningful short positions. The ORTEX short score of 28 — sitting at the 86th percentile rank for the score's recent history — does reflect some relative attention, but in the context of sub-0.2% SI, that is more a function of volatility than any coordinated bearish campaign.
Two elements from recent SEC filings are worth noting. A 424B3 shelf registration appeared at end of March, which formally keeps a secondary offering on the table. That may weigh on the stock's ability to rerate sharply on good news alone, given the company's market cap of roughly $123 million and the dilution optionality it implies. Soleus Capital Management holds close to 20% of shares outstanding, making the stock particularly sensitive to any large holder positioning changes.
The earnings history adds useful texture. The last two major releases produced day-one declines of around 2% and 3.6% respectively, with five-day losses extending to nearly 5% and 10%. The company does carry a strong EPS surprise track record — its factor score ranks in the 84th percentile — so beats have happened. The question heading into May 7 is whether a beat can overcome the broader headwinds around the stock's commercial ramp and margin trajectory that drove the recent target reductions. Watch management commentary on Focal One system placements and any update to full-year revenue guidance for the clearest read on where sentiment goes next.
See the live data behind this article on ORTEX.
Open EDAP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
